Ubs Group Ag Fennec Pharmaceuticals Inc. Transaction History
Ubs Group Ag
- $555 Billion
- Q2 2025
A detailed history of Ubs Group Ag transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Ubs Group Ag holds 13,024 shares of FENC stock, worth $120,472. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,024
Previous 26,254
50.39%
Holding current value
$120,472
Previous $159,000
32.08%
% of portfolio
0.0%
Previous 0.0%
Shares
32 transactions
Others Institutions Holding FENC
# of Institutions
80Shares Held
14MCall Options Held
10KPut Options Held
83.8K-
Southpoint Capital Advisors LP New York, NY4.08MShares$37.7 Million0.98% of portfolio
-
Sonic Gp LLC Honolulu, HI2.41MShares$22.3 Million33.54% of portfolio
-
Solas Capital Management, LLC Darien, CT2.23MShares$20.7 Million12.03% of portfolio
-
Black Rock Inc. New York, NY1.19MShares$11 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA967KShares$8.95 Million0.0% of portfolio
About FENNEC PHARMACEUTICALS INC.
- Ticker FENC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,067,300
- Market Cap $241M
- Description
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...